Services
The CPL has developed the methodological expertise required to support clinical trials and investigations of cellular therapies as follows:
- separation and selection of human peripheral blood lymphocyte (PBL) subsets, culture of tumor infiltrating lymphocytes (TIL) or lymph node lymphocytes (LNL) from tumor tissue, and tumor- involved or tumor-draining lymph nodes, respectively;
- culture and modification of peripheral blood-derived lymphocytes, including cytokine-activated T cells (killer T cells), activated natural killer cells (A-NK), and purified CD8+ or CD4+ T cells;
- culture and expansion of cells derived from normal tissues, e.g., skin or synovium, for use in gene therapy or cellular treatments;
- selection and culture of DC derived from monocytes in the peripheral blood or from stem cells, using peripheral blood obtained from patients with cancer;
- evaluation of cellular products for functional activity and cellular phenotypes;
- performance of gene transfers into T cells, fibroblasts, dendritic cells, or tumor cells and selection of genetically-modified cells;
- expansion of stem cells from including neural, mesenchymal and hematopoietic precursors; and
- preparation of cellular and peptide products for delayed-type hypersensitivity (DTH) testing, vaccination, and intratumoral, intranodal, intralymphatic, or intravenous administration for therapy.
More detailed descriptions of services are available here